Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of regorafenib in patients aged 70 and older with metastatic colorectal adenocarcinoma
2015-002086-29Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in colorectal cancer (CRC), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoints: Efficacy and Tolerance. Started Jul 2015; status: completed.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2015-002086-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002086-29.